{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04475523: Phase 1 Interventional Completed Solid Tumor
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03729596: Phase 1/Phase 2 Interventional Terminated Squamous Cell Carcinoma of Head and Neck
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01681290: Phase 2 Interventional Completed Diabetic Peripheral Neuropathy
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:abrezekimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04702880: Phase 2 Interventional Active, not recruiting Extensive-stage Small Cell Lung Cancer
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02514239: Phase 1 Interventional Completed Multiple Myeloma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03989362: Phase 2 Interventional Completed Cancer
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04097821: Phase 1/Phase 2 Interventional Completed Myelofibrosis
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04627025: Phase 3 Interventional Completed Short Bowel Syndrome
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04165317: Phase 3 Interventional Active, not recruiting Non-muscle Invasive Bladder Cancer
(2019)
Source URL:
Class:
PROTEIN
